GENTEX CORP
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Unaudited Condensed Consolidated Financial Statements
(1) Basis of Presentation
The accompanying Unaudited Condensed Consolidated Financial Statements of Gentex Corporation and Subsidiaries ("Gentex" or the "Company") included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission as defined in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 270 for interim financial information, and in accordance with financial standards generally accepted in the United States of America ("GAAP"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these Unaudited Condensed Consolidated Financial Statements be read in conjunction with the financial statements and notes thereto included in the Company's 2025 annual report on Form 10-K. In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements contain all adjustments considered necessary for a fair presentation of the financial position of the Company as of June 30, 2026, and the results of operations and cash flows for the interim periods presented.
(2)Adoption of New Accounting Standards
In March 2024, the Securities and Exchange Commission ("SEC") issued Final Rule No. 33-11275, "The Enhancement and Standardization of Climate-Related Disclosures for Investors." If such rule were to become effective, the rule would require disclosure of climate-related information outside of the audited financial statements and disclosure in the footnotes to such financial statements addressing specified financial statement effects of severe weather events and other natural conditions above certain financial thresholds, certain carbon offsets and renewable energy credits or certificates, if material. Such disclosure requirements were scheduled to begin phasing in for fiscal years beginning on or after January 1, 2025. In April of 2024, the SEC exercised its discretion to voluntarily stay the effective date of the final rules pending completion of certain judicial review. In 2025, the SEC withdrew its defense of the climate disclosure rule and litigation has been held in abeyance. In May of 2026, the SEC voted to propose rescinding this climate-related disclosure rule in its entirety. The public comment period closed August 3, 2026. A final rescission will still require the SEC to complete notice and comment rule making. Since rescission is not yet final, the Company continues to evaluate the potential impact of compliance, as well as compliance with similar rules of other jurisdictions.
In November 2024, the FASB issued ASU No. 2024-03, "Disaggregation of Income Statement Expenses (Subtopic 220-40)." The ASU requires public business entities to disaggregate, in a tabular presentation, certain income statement expenses into different categories, such as purchases of inventory, employee compensation, depreciation, and intangible asset amortization. The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Companies have the option to apply the guidance either on a retrospective or prospective basis, and early adoption is permitted. In January 2025, the FASB issued ASU No. 2025-01, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date." This ASU amends the effective date of ASU 2024-03 to clarify that all public business entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting these ASU's on the Consolidated Financial Statements and related disclosures.
In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity ("VIE"), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIE's. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the guidance and the impact on its future Consolidated Financial Statements.
In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which introduces a practical expedient for the application of the current expected credit loss model to current accounts receivable and contract assets in which all entities can assume that current conditions as of the balance sheet date do not change for the remaining life of the assets. This ASU was effective for the Company in the first quarter of 2026 and did not have a material impact on the Company's Consolidated Financial Statements and disclosures.
In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. This ASU updates the cost capitalization threshold for internal-use software development costs by removing all references to software project development stages and providing new guidance on how to evaluate whether the probable-to-complete recognition threshold has been met. ASU 2025-06, which can be applied prospectively, retrospectively, or with a modified transition approach, is effective for annual periods beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its Consolidated Financial Statements and disclosures.
In November 2025, the FASB issued ASU 2025-09, Derivatives and Hedging - Hedge Accounting Improvements (Topic 815), which amends certain aspects of the hedge accounting guidance to better align financial reporting with the economics of an entity's risk management activities. ASU 2025-09 is effective for annual and interim periods beginning after December 15, 2026. Early adoption is permitted and is effective on a prospective basis. The Company is currently evaluating the impact that the adoption of this standard will have on its Consolidated Financial Statements and disclosures.
In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements("ASU 2025-11"). This ASU enhances consistency in interim reporting for all entities by clarifying interim disclosure requirements and the form and content of interim financial statements in accordance with GAAP. ASU 2025-11, which can be applied prospectively or retrospectively to any and all prior periods presented in the financial statements, is effective for the interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its Consolidated Financial Statements and related disclosures.
(3)Goodwill and Other Intangible Assets
Goodwill represents the cost of an acquisition in excess of the fair values assigned to identifiable net assets acquired. The change in the carrying value of Goodwill by segment is as follows:
| Amount | |
|---|---|
| Automotive Products | |
| Beginning balance as of January 1, 2026 | $309,709,522 |
| Period activity | — |
| Balance as of June 30, 2026 (1) | $309,709,522 |
| Premium Audio Products | |
| Beginning balance as of January 1, 2026 | $12,713,758 |
| Acquisitions (including measurement period adjustments) (see Note 16) | 3,765,220 |
| Balance as of June 30, 2026 (1) | $16,478,978 |
| Other | |
| Beginning balance as of January 1, 2026 | $34,788,639 |
| Foreign currency adjustment | (127,317) |
| Balance as of June 30, 2026 | $34,661,322 |
| Gross carrying value at June 30, 2026 | $38,326,026 |
| Accumulated impairment charges | (3,664,704) |
| Net carrying value at June 30, 2026 | $34,661,322 |
| Total Goodwill, net | $360,849,822 |
| (1) The gross carrying values of goodwill in the Automotive Products and Premium Audio Products segments are equal to their net carrying values as there have been no impairments of goodwill within these segments. | |
In addition to annual impairment testing, which is performed as of the first day of the Company's fourth quarter, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions in determining fair value of goodwill or other intangible assets, thus resulting in the need for interim impairment testing, including: long-term revenue growth projections; profitability; discount rates; recent market valuations from transactions by comparable companies; volatility in the Company's market capitalization; and general industry, market, and macroeconomic conditions. No such events or circumstances that might negatively impact the key assumptions related to goodwill were observed during the second quarter of 2026 and, as such, nothing indicated the need for interim impairment testing.
During the first quarter of 2026, as a result of costs to develop the Company's In-Process Research and Development ("In Process R&D") continuing to exceed original estimates, as well as delays in the expected timing of commercialization of the related technology, management approved and began executing a plan to cease operations at the facility where its Vaporsens In-Process R&D activities were conducted. This plan included the termination of substantially all employees associated with those activities. As a result, the Company discontinued further development of the underlying technology and shifted its strategy to the potential sale of the related assets. These actions represented a significant adverse change in the extent and manner in which the In-Process R&D was expected to be used and in its projected future cash flows, indicating that the carrying value of the asset may not be recoverable. Accordingly, the Company recorded an impairment charge of $2.8 million in the first quarter of 2026 and, as such, it is included in the results for the six months ended June 30, 2026, to reduce the carrying amount of the asset to its estimated fair value. The estimated fair value was determined based on the Company's estimate of the expected selling price of the asset, taking into consideration available market information and indicative third-party interest, as applicable.
The Company's patents and intangible assets and related change in carrying values are set forth in the tables below, including the Vaporsens In-Process R & D, which has been previously disclosed.
| Other Intangible Assets | Gross | Accumulated Amortization | Net | Assumed Useful Life |
|---|---|---|---|---|
| Gentex Patents | $40,145,801 | $(29,223,269) | $10,922,532 | Various |
| Other Intangible Assets | ||||
| HomeLink® Trade Names and Trademarks | $52,000,000 | $— | $52,000,000 | Indefinite |
| HomeLink® Technology | 180,000,000 | (180,000,000) | — | 12 years |
| Existing Customer Platforms | 43,000,000 | (43,000,000) | — | 10 years |
| Exclusive Licensing Agreement | 96,000,000 | — | 96,000,000 | Indefinite |
| BioCenturion LLC ("BioCenturion") Trade Names and Trademarks | 640,000 | (106,667) | 533,333 | 10 years |
| BioCenturion Developed Technology | 2,300,000 | (319,445) | 1,980,555 | 12 years |
| eSight Developed Technology | 12,000,000 | (2,666,667) | 9,333,333 | 12 years |
| eSight Trade Names and Trademarks | 870,000 | (193,333) | 676,667 | 12 years |
| BioConnect Trade Names and Trademarks | 845,310 | (73,489) | 771,821 | 12 years |
| BioConnect Developed Technology | 5,283,178 | (459,303) | 4,823,875 | 12 years |
| BioConnect Customer Relationships | 1,690,617 | (146,977) | 1,543,640 | 10 years |
| Vaporsens In-Process R&D | 3,000,000 | — | 3,000,000 | Indefinite |
| Argil Developed Technology | 6,278,132 | (392,383) | 5,885,749 | 12 years |
| Air-Craftglass Developed Technology | 1,507,778 | (188,472) | 1,319,306 | 12 years |
| Guardian Trade Names | 1,300,000 | (216,667) | 1,083,333 | 12 years |
| Guardian Developed Technology | 6,800,000 | (1,133,333) | 5,666,667 | 12 years |
| Total Other Intangible Assets | $413,515,015 | $(228,896,736) | $184,618,279 | |
| Total Patents & Other Intangible Assets | $453,660,816 | $(258,120,005) | $195,540,811 | |
| Other Intangible Assets | Gross | Accumulated Amortization | Net | Assumed Useful Life |
|---|---|---|---|---|
| Gentex Patents | $39,769,415 | $(28,758,462) | $11,010,953 | Various |
| Other Intangible Assets | ||||
| HomeLink® Trade Names and Trademarks | $52,000,000 | $— | $52,000,000 | Indefinite |
| HomeLink® Technology | 180,000,000 | (180,000,000) | — | 12 years |
| Existing Customer Platforms | 43,000,000 | (43,000,000) | — | 10 years |
| Exclusive Licensing Agreement | 96,000,000 | — | 96,000,000 | Indefinite |
| BioCenturion Trade Names and Trademarks | 640,000 | (74,667) | 565,333 | 10 years |
| BioCenturion Developed Technology | 2,300,000 | (223,611) | 2,076,389 | 12 years |
| eSight Developed Technology | 12,000,000 | (2,166,667) | 9,833,333 | 12 years |
| eSight Trade Names and Trademarks | 870,000 | (157,083) | 712,917 | 12 years |
| BioConnect Trade Names and Trademarks | 874,320 | (32,254) | 842,066 | 12 years |
| BioConnect Developed Technology | 5,465,061 | (241,908) | 5,223,153 | 12 years |
| BioConnect Customer Relationships | 1,748,640 | (77,411) | 1,671,229 | 10 years |
| Vaporsens In-Process R&D | 5,800,000 | — | 5,800,000 | Indefinite |
| Argil Developed Technology | 6,278,132 | (130,794) | 6,147,338 | 12 years |
| Air-Craftglass Developed Technology | 1,507,778 | (125,649) | 1,382,129 | 12 years |
| Guardian Trade Names | 1,300,000 | (162,500) | 1,137,500 | 12 years |
| Guardian Developed Technology | 6,800,000 | (850,000) | 5,950,000 | 12 years |
| Total Other Intangible Assets | $416,583,931 | $(227,242,544) | $189,341,387 | |
| Total Patents & Other Intangible Assets | $456,353,346 | $(256,001,006) | $200,352,340 | |
Amortization expense of patents and intangible assets was approximately $1.2 million and $2.4 million during the three and six months ended June 30, 2026, respectively, compared to approximately $4.7 million and $9.3 million during the three and six months ended June 30, 2025, respectively.
Excluding the impact of any future acquisitions, the Company estimates amortization expense to be approximately $2.4 million for the remainder of the year ending December 31, 2026, $5 million for each of the years ending December 31, 2027, and December 31, 2028, respectively, and $4 million for each of the years ended December 31, 2029, and December 31, 2030, respectively.
(4)Investments
Available for sale securities
The Company follows the provisions of Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, for its financial assets and liabilities, and for its non-financial assets and liabilities subject to fair value measurements. ASC 820 provides a framework for measuring the fair value of assets and liabilities. This framework is intended to provide increased consistency in how fair value determinations are made under various existing accounting standards that permit, or in some cases, require estimates of fair-market value. This standard also expanded financial statement disclosure requirements with respect to a company’s use of fair-value measurements, including the effect of such measurements on earnings. The cost of securities sold is based on the specific identification method.
The Company determines the fair value of its asset-backed securities, municipal bonds, and corporate bonds by utilizing monthly valuation statements that are provided by its broker. The broker determines the investment valuation by utilizing the bid price in the market and also refers to third party sources to validate valuations, and as such are classified as Level 2 assets.
The Company's certificates of deposit are classified as available for sale and are considered as Level 1 assets. These investments are carried at cost, which approximates fair value.
Equity Method Investment - ASA
The Company has a 50% non-controlling ownership interest in ASA Electronics, LLC and Subsidiary ("ASA"), that was obtained in conjunction with the acquisition of VOXX International Corporation ("VOXX") on April 1, 2025 (see Note 16) and is accounted for in accordance with ASC 323, Investments – Equity Method and Joint Venture. ASA acts as a distributor of mobile electronics, specifically designed for niche markets, including: RV's; buses; and commercial, heavy duty, agricultural, construction, powersport, and marine vehicles. ASC 810, Consolidation, requires the Company to evaluate non-consolidated entities periodically, and as circumstances change, to determine if an implied controlling interest exists. The balance of the Company's investment in ASA was $20.1 million and $20.0 million as of June 30, 2026 and December 31, 2025, respectively, and included in Long-term investments on the accompanying Unaudited Condensed Consolidated Balance Sheets.
Technology Investments
The Company also periodically makes strategic investments in the non-marketable debt or equity securities of other non-consolidated third parties ("Technology Investments"). Such Technology Investments totaled $115.3 million as of June 30, 2026, and are recorded in long-term investments on the accompanying Unaudited Condensed Consolidated Balance Sheet. Such Technology Investments totaled approximately $146.6 million as of December 31, 2025, of which $144.9 million and $1.7 million are included in long-term investments and short-term investments, respectively, on the accompanying Unaudited Condensed Consolidated Balance Sheets. Depending on the form of investment, and the degree of influence the Company has over the investee, the Company primarily accounts for the Technology Investments in accordance with ASC 321, Investments - Equity Securities or ASC 323, Investments – Equity Method and Joint Venture. The Company accounts for equity securities in non-controlled affiliates through which the Company exercises significant influence but does not have control over the investee under the equity method, with the Company’s share of the earnings or losses of non-controlled affiliates recognized within Other (loss) income, net, in the Company's accompanying Unaudited Condensed Consolidated Statements of Income. All other Technology Investments that the Company holds are primarily accounted for under the measurement alternative of ASC 321. Under the measurement alternative, the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.
During the first quarter of 2026, the Company recognized a loss of $1.7 million within Other, net, related to warrants held in one of the Company's technology investments that expired unexercised during that quarter.
During the six months ended June 30, 2026, the Company recorded an other-than-temporary impairment charge of $12.2 million related to two of its technology investments, which are included in Investment (loss) income, net, on the accompanying Unaudited Condensed Consolidated Statement of Income. During the first quarter of 2026, the Company identified indicators of impairment related to the investment, including a sustained deterioration in the entity's operating results and financial condition, as well as the execution of a forbearance agreement associated with outstanding loans from the Company to the investee totaling approximately $5.0 million (exclusive of credit reserves) as of March 31, 2026, and June 30, 2026. Based on these factors, the Company determined that the decline in fair value of its investment was other-than-temporary. The Company concluded that the estimated fair value of its equity interest was negligible, as the investee's enterprise value was not expected to be sufficient to satisfy the Company's outstanding loan exposure. Accordingly, the Company recorded a full impairment charge to reduce the carrying amount of the investment to zero.
From time to time, the Company makes loans in the ordinary course of business to certain of its technology investees. Such loans vary in length and are interest bearing, and as such are not deemed to be additional investments in the technology investees as the parties intend for the loans to be repaid. These loans are classified within Prepaid expenses and other and Patents and other assets, net, on the accompanying Unaudited Condensed Consolidated Balance Sheets based on the maturity dates of the loans. The Company estimates an allowance for credit losses for these loans receivable in accordance with ASC 326, Financial Instruments - Credit Losses. This allowance reflects the Company's estimate of expected credit losses over the contractual life of the loans, considering historical loss experience, current conditions, and reasonable and supportable forecasts. The estimate is developed using a combination of quantitative data and qualitative factors, including borrower creditworthiness, loan-specific risk characteristics, macroeconomic trends, and other relevant information, all of which is updated quarterly. The allowance is adjusted through a provision for credit losses in the Company's Unaudited Condensed Consolidated Statements of Income. For the three and six months ended June 30, 2026, the Company recorded an increase to the credit loss allowance of $2.9 million and $5.1 million, respectively. The total allowance for credit losses attributable to the Company's loans receivable were $12.5 million and $7.4 million at June 30, 2026 and December 31, 2025, respectively. The balance of the loans included in Prepaid expenses and other on the accompanying Unaudited Condensed Consolidated Balance Sheets was $18.6 million and $13.5 million at June 30, 2026 and December 31, 2025, respectively, net of credit loss allowances. The balance of the loans included in Patents and other assets, net, on the accompanying Unaudited Condensed Consolidated Balance Sheets was $1.3 million and $7.9 million, at June 30, 2026 and December 31, 2025, respectively, net of credit loss allowances.
Assets or liabilities that have recurring fair value measurements are shown below as of June 30, 2026 and December 31, 2025.
| Fair Value Measurements at Reporting Date Using | ||||
|---|---|---|---|---|
| Total as of | Quoted Prices inActive Markets forIdentical Assets | Significant OtherObservableInputs | SignificantUnobservableInputs | |
| Description | June 30, 2026 | (Level 1) | (Level 2) | (Level 3) |
| Cash & Cash Equivalents | $233,444,229 | $233,444,229 | $— | $— |
| Short-Term Investments: | ||||
| Corporate Bonds | 7,893,830 | — | 7,893,830 | — |
| Municipal Bonds | 486,550 | — | 486,550 | — |
| Other | 986,324 | 986,324 | — | — |
| Long-Term Investments: | ||||
| Asset-backed Securities | 31,752,977 | — | 31,752,977 | — |
| Corporate Bonds | 54,607,350 | — | 54,607,350 | — |
| Municipal Bonds | 16,709,266 | — | 16,709,266 | — |
| Total | $345,880,526 | $234,430,553 | $111,449,973 | $— |
| Fair Value Measurements at Reporting Date Using | ||||
|---|---|---|---|---|
| Total as of | Quoted Prices inActive Markets forIdentical Assets | Significant OtherObservableInputs | SignificantUnobservableInputs | |
| Description | December 31, 2025 | (Level 1) | (Level 2) | (Level 3) |
| Cash & Cash Equivalents | $145,645,715 | $145,645,715 | $— | $— |
| Short-Term Investments: | ||||
| Corporate Bonds | 2,747,293 | — | 2,747,293 | — |
| Other | 924,658 | 924,658 | — | — |
| Long-Term Investments: | ||||
| Asset-backed Securities | 35,709,133 | — | 35,709,133 | — |
| Corporate Bonds | 55,596,276 | — | 55,596,276 | — |
| Municipal Bonds | 16,840,001 | — | 16,840,001 | |
| Total | $257,463,076 | $146,570,373 | $110,892,703 | $— |
The amortized cost, unrealized gains and losses, and market value of investment securities are shown below as of June 30, 2026 and December 31, 2025.
| Unrealized | ||||
|---|---|---|---|---|
| Cost | Gains | Losses | Market Value | |
| Short-Term Investments: | ||||
| Corporate Bonds | $7,882,231 | $12,262 | $(663) | $7,893,830 |
| Municipal Bonds | 485,249 | 1,301 | — | 486,550 |
| Other | 986,324 | — | — | 986,324 |
| Long-Term Investments: | ||||
| Asset-backed Securities | 31,047,299 | 741,038 | (35,360) | 31,752,977 |
| Corporate Bonds | 55,019,633 | 280,118 | (692,401) | 54,607,350 |
| Municipal Bonds | 16,784,771 | 150,709 | (226,214) | 16,709,266 |
| Total | $112,205,507 | $1,185,428 | $(954,638) | $112,436,297 |
| Unrealized | ||||
|---|---|---|---|---|
| Cost | Gains | Losses | Market Value | |
| Short-Term Investments: | ||||
| Corporate Bonds | $2,725,824 | $21,469 | $— | $2,747,293 |
| Other | 924,658 | — | — | 924,658 |
| Long-Term Investments: | ||||
| Asset-backed Securities | 34,581,117 | 1,128,541 | (525) | 35,709,133 |
| Corporate Bonds | 55,218,308 | 684,752 | (306,784) | 55,596,276 |
| Municipal Bonds | 16,662,335 | 351,044 | (173,378) | 16,840,001 |
| Total | $110,112,242 | $2,185,806 | $(480,687) | $111,817,361 |
Unrealized losses on available-for-sale securities as of June 30, 2026, are as follows:
| Aggregate Unrealized Losses | Aggregate Fair Value of Investments | |
|---|---|---|
| Loss duration of less than one year | $801,180 | $49,514,191 |
| Loss duration of greater than one year | 153,458 | 2,465,536 |
| Total | $954,638 | $51,979,727 |
Unrealized losses on available-for-sale securities as of December 31, 2025, are as follows:
| Aggregate Unrealized Losses | Aggregate Fair Value of Investments | |
|---|---|---|
| Loss duration of less than one year | $272,327 | $24,149,316 |
| Loss duration of greater than one year | 208,360 | 5,471,407 |
| Total | $480,687 | $29,620,723 |
The Company utilizes the guidance provided by ASC 326 -Financial Instruments - Credit Losses, which provides an accounting model for purchased financial assets with credit deterioration since their origination, to determine whether any of the available-for-sale debt securities held by the Company are impaired. No such investments were considered to be impaired during the periods presented. The Company has the intention and current ability to hold its debt investments until any amortized cost basis has been recovered.
Fixed income securities as of June 30, 2026 have contractual maturities as follows:
| Due within one year | $8,380,380 |
|---|---|
| Due between one and five years | 45,400,500 |
| Due over five years | 57,669,093 |
| $111,449,973 |
(5)Inventories, net
Inventories consisted of the following at the respective balance sheet dates:
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Raw materials | $278,080,196 | $280,645,041 |
| Work-in-process | 79,801,431 | 64,473,370 |
| Finished goods | 161,068,784 | 171,135,206 |
| Total Inventory | $518,950,411 | $516,253,617 |
(6)Earnings Per Share
The Company has unvested share-based payment awards with a right to receive non-forfeitable dividends, which are considered participating securities under ASC 260, Earnings Per Share. The Company allocates earnings to participating securities and computes earnings per share using the two-class method. Under the two-class method, net income per share is computed by dividing net income allocated to common shareholders by the weighted average number of common shares outstanding for the period. In applying the two-class method, net income is allocated to both common shares and participating securities based on their respective weighted average shares outstanding for the period. For a period of net loss, net loss is not allocated to participating securities.
The following table sets forth the computation of basic and diluted net income per common share under the two-class method for the three and six months ended June 30, 2026 and 2025:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Basic Earnings Per Share | ||||
| Net Income Attributable to Gentex Corporation | $114,689,417 | $96,039,584 | $213,144,560 | $190,913,629 |
| Less: Dividends and undistributed earnings allocated to participating securities | 1,879,597 | 1,412,231 | 3,439,528 | 3,473,779 |
| Net Income available to common shareholders | $112,809,820 | $94,627,353 | $209,705,032 | $187,439,850 |
| Basic weighted average shares outstanding | 208,580,380 | 219,631,876 | 209,720,391 | 221,376,755 |
| Net Income per share - Basic | $0.54 | $0.43 | $1.00 | $0.85 |
| Diluted Earnings Per Share | ||||
| Allocation of Net Income used in basic computation | $112,809,820 | $94,627,353 | $209,705,032 | $187,439,850 |
| Reallocation of undistributed earnings | 37 | — | 45 | 77 |
| Net Income available to common shareholders - Diluted | $112,809,857 | $94,627,353 | $209,705,077 | $187,439,927 |
| Number of shares used in basic computation | 208,580,380 | 219,631,876 | 209,720,391 | 221,376,755 |
| Additional weighted average dilutive common stock equivalents | 5,346 | — | 3,652 | 8,845 |
| Diluted weighted average shares outstanding | 208,585,726 | 219,631,876 | 209,724,043 | 221,385,600 |
| Net Income per share - Diluted | $0.54 | $0.43 | $1.00 | $0.85 |
| Shares related to stock plans not included in diluted average common shares outstanding because their effect would be anti-dilutive | 2,453,462 | 3,694,254 | 2,560,291 | 3,386,076 |
(7)Stock-Based Compensation Plans
As of June 30, 2026, the Company hadtwo equity incentive plans in effect, which include the Gentex Corporation 2026 Omnibus Plan ("2026 Omnibus Plan"), and an employee stock purchase plan. Those plans and any prior material amendments thereto have previously been approved by shareholders.
The 2026 Omnibus Plan provides for the potential awards to: i) employees; and ii) non-employee directors of the Company or its subsidiaries, which awards may be stock options (both incentive stock options and non-qualified stock options), appreciation rights, restricted stock units, performance share awards and performance units and other awards that are stock-based, cash-based or a combination of both. The 2026 Omnibus Plan amended and restated in its entirety the Gentex Corporation 2019 Omnibus Plan (" 2019 Omnibus Plan"). Any existing awards previously granted under the 2019 Omnibus Plan (or any Prior Plans as defined therein) will continue to remain outstanding in accordance with their terms and be governed thereby. The purpose of this Gentex Corporation 2026 Omnibus Incentive Plan is to attract and retain directors, officers, and other employees Gentex Corporation and its Subsidiaries and to motivate and provide to such persons incentives and rewards for performance. From and after May 21, 2026, the date on which the shareholders approved the Gentex Corporation 2026 Omnibus Incentive Plan, no new Awards will be granted under the Gentex Corporation 2019 Omnibus Incentive Plan.
Readers should refer to Note 5 of the Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the calendar year ended December 31, 2025, for additional information related to the 2019 Omnibus Plan (and any Prior Plans).
The Company recognized total compensation expense for share-based payments of $10.0 million and $20.5 million for the three and six months ended June 30, 2026, respectively, compared to $7.6 million and $16.3 million for the three and six months ended June 30, 2025, respectively. A portion of the compensation cost for share-based payment awards is capitalized as part of inventory.
2019 Omnibus Incentive Plan
The purpose of the 2019 Omnibus Plan is to attract and retain employees, officers, and directors of the Company and its subsidiaries and to motivate and provide such persons' incentives and rewards for performance. Pursuant to the terms of the 2019 Omnibus Plan, each type of award counts against the available shares based on a predetermined conversion rate (shown in the table below). As of June 30, 2026,12,853,474 share awards were made under the 2019 Omnibus Plan, resulting in 38,498,119 shares granted of the 45,000,000 total shares that were available to be issued under the 2019 Omnibus Plan. The shares issued are presented net of shares from canceled/expired options and shares. From and after May 21, 2026, the date on which the shareholders approved the Gentex Corporation 2026 Omnibus Incentive Plan, no new Awards will be granted under the Gentex Corporation 2019 Omnibus Incentive Plan.
| Shares Granted | Conversion Rate | Total Shares Under 2019 Omnibus Plan | |
|---|---|---|---|
| Non-Qualified Stock Options | 4,472,871 | 1.00 | 4,472,871 |
| Restricted Stock | 6,634,145 | 4.06 | 26,934,629 |
| Performance Shares | 1,746,458 | 4.06 | 7,090,619 |
| Total | 12,853,474 | 38,498,119 |
2026 Omnibus Incentive Plan
The purpose of the 2026 Omnibus Plan is to attract and retain employees, officers, and directors of the Company and its subsidiaries and to motivate and provide such persons' incentives and rewards for performance. Pursuant to the terms of the 2026 Omnibus Plan, each type of award counts against the available shares based on a predetermined conversion rate (shown in the table below). As of June 30, 2026,407,858 share awards have been made under the 2026 Omnibus Plan, resulting in 1,141,562 shares granted of the 30,000,000 total shares available to be issued under the 2026 Omnibus Plan. The shares issued are presented net of shares from canceled/expired options and shares.
| Shares Granted | Conversion Rate | Total Shares Under 2026 Omnibus Plan | |
|---|---|---|---|
| Non-Qualified Stock Options | 51,691 | 1.00 | 51,691 |
| Restricted Stock | 356,167 | 3.06 | 1,089,871 |
| Total | 407,858 | 1,141,562 |
Employee Stock Options
Under the 2026 Omnibus Plan, 2019 Omnibus Plan and the Prior Plans, the option exercise price equals the stock’s market price on the date of grant. The options vest afterone tofive years and expire after five toten years. As of June 30, 2026, there was $2.8 million of unearned compensation cost associated with stock options granted under the 2026 Omnibus Plan, 2019 Omnibus Incentive Plan and the Prior Plans, which is expected to be recognized over the remaining vesting periods.
The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions for the indicated periods:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Dividend Yield (1) | 1.72% | 1.63% | 1.71% | 1.63% |
| Expected volatility (2) | 26.14% | 24.85% | 26.02% | 25.23% |
| Risk-free interest rate (3) | 4.19% | 3.79% | 4.06% | 3.88% |
| Expected term of options (years) (4) | 4.14 | 4.14 | 4.15 | 4.14 |
| Weighted-avg. grant date fair value | $5.93 | $4.87 | $5.47 | $5.11 |
Represents the Company’s estimated cash dividend yield over the expected term of option grant.
Amount is determined based on analysis of historical price volatility of the Company’s common stock. The expected volatility is based on the daily percentage change in the price of the stock over a period equal to the expected term of the option grant.
Represents the U.S. Treasury yield over the expected term of the option grant.
Represents the period of time that options granted are expected to be outstanding. Based on analysis of historical option exercise activity, the Company has determined that all employee groups exhibit similar exercise and post-vesting termination behavior.
Restricted Shares
Restricted shares awarded under the 2026 Omnibus Plan, 2019 Omnibus Plan and the Prior Plans entitle the shareholder to all rights of common stock ownership, except that the shares may not be sold, transferred, pledged, exchanged, or otherwise disposed of during the restriction period. The restriction period is determined by the Compensation Committee, appointed by the Board of Directors, but may not exceedten years under the terms of such plans. As of June 30, 2026, the Company had unearned stock-based compensation of $55.4 million associated with the restricted stock grants issued under the 2026 Omnibus Plan, 2019 Omnibus Plan and the Prior Plans. The unearned stock-based compensation related to these grants is being amortized to compensation expense over the applicable restriction periods. Compensation expense from restricted stock grants for the three and six months ended June 30, 2026 was $6.4 million and $12.5 million, respectively, compared to $5.0 million and $10.9 million for the three and six months ended June 30, 2025, respectively.
Performance Shares
Performance shares awarded under the 2019 Omnibus Plan are considered performance condition awards as attainment is based on the Company's performance relative to pre-established metrics. The fair value of such performance share awards was determined using the Company's average closing stock price on the twenty days preceding the date of grant. The expected attainment of the metrics for these awards is then analyzed each reporting period, and the related expense is adjusted based on expected attainment, if the then expected attainment differs from previous expectations. The cumulative effect on current and prior periods of a change in expected attainment is recognized in the period of change.
As of June 30, 2026, the Company had unearned stock-based compensation of $18.4 million associated with these performance share grants. The unearned stock-based compensation related to these grants is being amortized to compensation expense over the applicable performance periods. Compensation expense related to these performance share grants for the three and six months ended June 30, 2026 was $1.9 million and $4.8 million, respectively, compared to $0.9 million and $2.0 million for the three and six months ended June 30, 2025, respectively.
As part of its objective of attracting and retaining management to fulfill the Company's strategic goals, the Compensation Committee recommended and the Board approved on February 16, 2023, a retention grant of performance share awards ("PSAs"). In addition to the retention of management, the PSAs have been granted to further align management goals with those of the Company's shareholders. For that reason, the PSAs have been granted with performance criteria and will be based upon achievement of the Company's relative total shareholder return ("TSR") over afour-year period (2023-2026), against a predetermined peer group. The grant date fair value of PSAs with TSR targets was determined using a Monte Carlo simulation. Compensation expense related to these retention grants was $0.5 million and $1.0 million during each of the three and six months ended June 30, 2026 and June 30, 2025, respectively.
Employee Stock Purchase Plan
The 2022 Gentex Corporation Employee Stock Purchase Plan covering 2,000,000 shares of common stock was approved by shareholders effective July 1, 2022. Under the plan, the Company sells shares at 85% of the stock's market price at date of purchase. Under ASC 718, Compensation - Stock Compensation, the 15% discounted value is recognized as compensation expense. As of June 30, 2026, the Company has issued 858,195 shares under this plan.
(8)Comprehensive Income (Loss)
Comprehensive income (loss) reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. For the Company, comprehensive income (loss)
represents net income adjusted for unrealized gains and losses on available for sale investment securities, foreign currency translation adjustments, and derivative instruments.
The following table presents the net changes in the Company's accumulated other comprehensive income (loss) by component (all amounts shown are net of tax):
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Foreign currency translation adjustments: | ||||
| Balance at beginning of period | $1,434,747 | $(6,162,966) | $(310,305) | $(5,817,736) |
| Other comprehensive income | 283,277 | 2,109,011 | 2,028,329 | 1,763,781 |
| Net current-period change | 283,277 | 2,109,011 | 2,028,329 | 1,763,781 |
| Balance at end of period | 1,718,024 | (4,053,955) | 1,718,024 | (4,053,955) |
| Unrealized gains (losses) on available for sale securities: | ||||
| Balance at beginning of period | 704,122 | 1,132,844 | 1,347,044 | (591,605) |
| Other comprehensive loss before reclassifications | (521,799) | 1,107,816 | (1,165,516) | 1,480,018 |
| Amounts reclassified from accumulated other comprehensive income (loss) | — | (599,514) | 795 | 752,733 |
| Net current-period change | (521,799) | 508,302 | (1,164,721) | 2,232,751 |
| Balance at end of period | 182,323 | 1,641,146 | 182,323 | 1,641,146 |
| Unrealized losses on derivatives: | ||||
| Balance at beginning of period | (916,269) | — | (768,985) | — |
| Other comprehensive loss before reclassifications | 726,620 | (1,235,940) | 631,563 | (1,235,940) |
| Amounts reclassified from accumulated other comprehensive Income (loss) | — | 252,100 | (52,227) | 252,100 |
| Net current-period change | 726,620 | (983,840) | 579,336 | (983,840) |
| Balance at end of period | (189,649) | (983,840) | (189,649) | (983,840) |
| Accumulated other comprehensive income (loss), end of period | $1,710,698 | $(3,396,649) | $1,710,698 | $(3,396,649) |
The following table presents details of reclassifications out of accumulated other comprehensive loss for the six months ended June 30, 2026 and 2025:
| Details about Accumulated Other Comprehensive Loss Components · Amounts Reclassified from Other Comprehensive Loss · Affected Line item in the Unaudited Condensed Consolidated Statements of Income | |||||
|---|---|---|---|---|---|
| Three Months Ended June 30, · Six Months Ended June 30, | |||||
| 2026 · 2025 · 2026 · 2025 | |||||
| Available for sale securities: | |||||
| Realized gain (loss) on sale of securities | $— | $758,879 | $(1,005) | $(952,826) | Other income (loss), net |
| Income tax effect | — | (159,365) | 210 | 200,093 | Provision for income taxes |
| Total net reclassifications for the period | $— | $599,514 | $(795) | $(752,733) | |
| Derivatives: | |||||
| Realized gain (loss) on settlement of derivatives | $— | $(373,205) | $77,316 | $(373,205) | Other income (loss), net |
| Income tax effect | $— | 121,105 | (25,089) | 121,105 | Provision for income taxes |
| Total net reclassifications for the period | $— | $(252,100) | $52,227 | $(252,100) | |
| Total reclassifications for the period | $— | $347,414 | $51,432 | $(1,004,833) | |
(9)Debt and Financing Arrangements
The Company has a credit agreement with PNC as the administrative agent and sole lender (the "Credit Agreement"), that provides for, among other things, athree-year unsecured revolving credit facility with a borrowing capacity of up to $350.0 million (the "Revolver"). Included in the Revolver is a $20.0 million sublimit for standby letters of credit and a $35.0 million sublimit for swingline loans, each subject to certain conditions. Funds are available under the Revolver for working capital, capital expenditures, and other lawful corporate purposes, including, but not limited to, acquisitions and common stock repurchases, subject in each case to compliance with certain financial covenants, as defined in the Credit Agreement. The maturity date of the Credit Agreement is October 1, 2028.
The obligations of the Company under the Credit Agreement are not secured, but are subject to certain covenants. The Credit Agreement contains customary representations and warranties and certain covenants that place certain limitations on the Company. As of June 30, 2026, there wasno outstanding balance on the Revolver and the Company was in compliance with all covenants under the Credit Agreement.
The Company's subsidiary, VOXX, which was acquired on April 1, 2025 (see Note 16), has a loan agreement with the shareholders of its joint venture in Onkyo Technology KK ("Onkyo"). The loan balance outstanding at June 30, 2026 was $3.7 million and is included in Short-term debt on the accompanying Unaudited Condensed Consolidated Balance Sheet, representing the portion of the loan payable to the joint venture partner. All amounts outstanding under the loan will mature and become payable on September 8, 2031. The loan may be prepaid subject to the approval of the board of directors of the joint venture and must be repaid if either a put or call option is exercised in accordance with the joint venture agreement. The rate of interest for the shareholder loan is 2.5% and the loan is secured by a second priority lien on and secured interest in all assets of Onkyo.
(10)Equity
The decrease in common stock for the six months ended June 30, 2026, was primarily due to the repurchases of 5.9 million shares, partially offset by the issuance of 1.2 million shares of the Company’s common stock, net of cancellations, under the Company’s stock-based compensation plans. The total net decrease for the six months ended June 30, 2026, was 4.7 million shares.
The Company recorded a cash dividend of $0.120 per share during the second quarter of 2026, as compared to a cash dividend of $0.120 per share during the second quarter of 2025. The second quarter 2026 dividend of $25.3 million was declared on May 26, 2026, and was paid on July 22, 2026.
(11)Contingencies
The Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business, including proceedings relating to, for example, product liability, intellectual property, safety and health, employment, regulatory, and other matters. Such matters are subject to many uncertainties and outcomes are not predictable. The Company does not believe, however, that at the current time any of these matters constitute material pending legal proceedings that will have a material adverse effect on the financial position or future results of operations or cash flows of the Company.
(12)Segment Reporting
ASC 280, Segment Reporting, requires that a public business entity report financial and descriptive information about its reportable operating segments, subject to certain aggregation criteria and quantitative thresholds. Operating segments are defined by ASC 280 as components of a public business entity about which separate financial information is available that is evaluated regularly by the chief operating decision-maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company's CODM is its Chief Executive Officer. The CODM evaluates performance and allocates resources based upon a number of factors, including the nature of the business, relevant industry, and profitability of the same, with the primary profit measure being income (loss) from operations of each segment. The CODM uses this information to evaluate the profitability of the Company's reportable segments and make decisions on future business plans.
The Company has identified nine distinct operating segments based on its products and internal organizational structure. These operating segments are disclosed by the Company under three reportable segments for financial reporting purposes, which are Automotive Products, Premium Audio Products, and Other. The Company's Automotive Products segment develops and manufactures digital vision and connected car products and electronics, including: interior and exterior electrochromic automatic-dimming rearview mirrors with and without electronic features; non-auto dimming rearview mirrors with and without electronic features; and other automotive electronics. The Company's Premium Audio Products segment designs, manufactures, markets, and distributes high quality audio equipment created to deliver superior sound quality and performance, including premium loudspeakers, architectural speakers, commercial and cinema speakers, outdoor speakers, wireless and Bluetooth speakers, A/V receivers, home theater systems, soundbars, and music streaming systems. The Company's Other segment includes the operating segments of Fire Protection, Dimmable Aircraft Windows, Nanofiber, Medical, Aftermarket, Consumer Electronics, and Biometrics, which do not meet quantitative thresholds for separate disclosure pursuant to ASC 280.
The segments share many common resources, infrastructures, and assets in the normal course of business. Thus, the Company does not report assets or capital expenditures by segment to the CODM.
The following table presents net sales and the significant expense categories that are included in reportable segment operating profit, which are regularly provided to the CODM:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net Sales: | ||||
| Automotive Products | $560,201,415 | $578,129,026 | $1,141,007,327 | $1,141,993,285 |
| Premium Audio Products | 51,687,407 | 44,490,597 | 103,558,368 | 44,490,597 |
| Other | 39,410,883 | 35,238,587 | 82,177,136 | 48,147,418 |
| Total | $651,299,705 | $657,858,210 | $1,326,742,831 | $1,234,631,300 |
| Cost of Goods Sold: | ||||
| Automotive Products | $360,996,565 | $372,449,869 | $748,546,659 | $747,947,061 |
| Premium Audio Products | 25,145,142 | 32,612,485 | 57,480,337 | 32,612,485 |
| Other | 24,160,271 | 27,504,953 | 51,091,194 | 37,047,264 |
| Total | $410,301,978 | $432,567,307 | $857,118,190 | $817,606,810 |
| Operating Expenses: | ||||
| Automotive Products | $73,594,270 | $76,596,788 | $148,353,437 | $147,673,613 |
| Premium Audio Products | 13,607,615 | 13,964,761 | 27,117,162 | 13,964,761 |
| Other | 12,457,448 | 16,209,219 | 29,155,729 | 23,878,875 |
| Total | $99,659,333 | $106,770,768 | $204,626,328 | $185,517,249 |
| Depreciation and Amortization: | ||||
| Automotive Products | $22,331,793 | $24,567,309 | $44,600,521 | $48,033,592 |
| Premium Audio Products | 105,396 | 168,533 | 206,600 | 168,533 |
| Other | 1,407,572 | 1,117,817 | 2,736,334 | 1,931,220 |
| Corporate | 1,929,168 | 1,517,715 | 3,886,726 | 2,747,098 |
| Total | $25,773,929 | $27,371,374 | $51,430,181 | $52,880,443 |
| Income (Loss) from Operations: | ||||
| Automotive Products | $125,610,580 | $130,045,214 | $244,107,231 | $246,372,611 |
| Premium Audio Products | 12,934,650 | (2,086,649) | 18,960,869 | (2,086,649) |
| Other | 2,793,164 | (9,438,430) | 1,930,213 | (12,778,721) |
| Total | $141,338,394 | 118,520,135 | $264,998,313 | $231,507,241 |
(13)Income Taxes
The effective tax rate was 16.5% for the three months ended June 30, 2026, compared to an effective tax rate of 17.2% for the three months ended June 30, 2025. The effective tax rate was 16.6% for the six months ended June 30, 2026, compared to an effective tax rate of 16.8% for the same period in 2025. Generally, effective tax rates for these periods differ from statutory federal income tax rates due to provisions for state and local income taxes, the foreign-derived deduction-eligible income tax deduction ("FDDEI"), and research and development tax credits.
(14)Revenue
The following table shows the Company’s Automotive Products revenue, Premium Audio Products revenue and Other revenue disaggregated by geographical location for Automotive and Premium Audio Products for the three and six months ended June 30, 2026 and 2025, respectively:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| Revenue | 2026 | 2025 | 2026 | 2025 |
| Automotive Products | ||||
| U.S. | $194,364,317 | $172,204,462 | $382,585,711 | $335,585,400 |
| Japan | 87,681,935 | 96,094,581 | 186,103,285 | 194,459,984 |
| Germany | 41,366,733 | 67,662,895 | 91,272,170 | 132,680,756 |
| Korea | 29,567,436 | 56,610,947 | 67,490,526 | 94,806,280 |
| Mexico | 52,308,291 | 45,702,656 | 102,405,657 | 93,351,532 |
| China | 29,389,361 | 35,081,549 | 59,585,842 | 76,035,949 |
| Other | 125,523,342 | 104,771,936 | 251,564,136 | 215,073,384 |
| Total Automotive Products | $560,201,415 | $578,129,026 | $1,141,007,327 | $1,141,993,285 |
| Premium Audio Products | ||||
| U.S. | $32,045,881 | $29,933,112 | $63,235,135 | $29,933,112 |
| Other | 19,641,526 | 14,557,485 | 40,323,233 | 14,557,485 |
| Total Premium Audio Products | $51,687,407 | 44,490,597 | $103,558,368 | 44,490,597 |
| Other | 39,410,883 | 35,238,587 | 82,177,136 | 48,147,418 |
| Total Revenue | $651,299,705 | $657,858,210 | $1,326,742,831 | $1,234,631,300 |
Revenue by geographic area may fluctuate based on many factors, including: exposure to local economic, political, and labor conditions; global supply chain constraints; unexpected changes in laws and regulations; unexpected changes in trade, monetary, or fiscal policy, including interest rates, foreign currency exchange rates, and changes in the rate of inflation in the U.S. and other foreign countries; labor strikes; armed conflicts and acts of terrorism and war; tariffs, quotas, customs and other import or export restrictions; and other trade barriers.
The following table disaggregates the Company’s Automotive, Premium Audio, and Other revenue by major source for the three and six months ended June 30, 2026 and 2025, respectively:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| Revenue | 2026 | 2025 | 2026 | 2025 |
| Automotive Products | ||||
| Automotive Mirrors & Electronics | $531,669,550 | $548,897,948 | $1,084,407,570 | $1,079,029,377 |
| HomeLink Modules* | 28,531,865 | 29,231,078 | 56,599,757 | 62,963,908 |
| Total Automotive Products | $560,201,415 | $578,129,026 | $1,141,007,327 | $1,141,993,285 |
| Premium Audio Products | ||||
| Premium Speaker Products | $37,352,998 | $32,430,491 | $71,918,245 | $32,430,491 |
| Premium Receiver Products | 14,334,409 | 12,060,106 | 31,640,123 | 12,060,106 |
| Total Premium Audio Products | $51,687,407 | $44,490,597 | $103,558,368 | $44,490,597 |
| Other | ||||
| Fire Protection Products | $8,272,590 | $8,082,207 | $17,099,759 | $14,799,977 |
| Windows Products | 6,520,379 | 3,996,515 | 14,854,779 | 8,887,501 |
| Medical Products | 361,016 | 245,421 | 714,631 | 632,256 |
| Aftermarket Products | 13,586,193 | 15,223,080 | 27,454,322 | 15,223,080 |
| Consumer Electronic Products | 7,903,080 | 7,477,039 | 16,264,843 | 7,477,039 |
| SAD | 39,973 | — | 39,973 | — |
| Biometric Products | 2,727,652 | 214,325 | 5,748,829 | 1,127,565 |
| Total Other | $39,410,883 | $35,238,587 | $82,177,136 | $48,147,418 |
| Total Revenue | $651,299,705 | $657,858,210 | $1,326,742,831 | $1,234,631,300 |
| *Excludes HomeLink revenue where HomeLink electronics are integrated into interior auto-dimming mirrors. | ||||
Sales Incentives
Sales incentives are offered to certain customers in the form of: (1) co-operative advertising allowances; (2) market development funds; (3) volume incentive rebates; and (4) other trade allowances. The Company accounts for sales incentives in accordance with ASC 606 "Revenue from Contracts with Customers" ("ASC 606"). These sales incentives represent variable consideration provided to customers. Depending on the specific facts and circumstances, either the most likely amount or expected value methods are utilized to estimate the effect of uncertainty on the amount of variable consideration to which the Company would be entitled. The most likely amount method considers the single most likely amount from a range of possible consideration amounts, while the expected value method is the sum of the probability-weighted amounts in a range of possible consideration amounts. Both methods are based upon the contractual terms of the incentives and historical experience with each customer. Except for other trade allowances, all sales incentives also require the customer to purchase the Company's products during a specified period of time. All sales incentives also require customers to claim the sales incentive within a certain time period (referred to as the "claim period") and claims are settled either by the customer claiming a deduction against an outstanding account receivable or by the customer requesting a cash payout. All costs associated with sales incentives are classified as a reduction of net sales. Although the Company makes its best estimate of such sales incentive liability, many factors, including significant unanticipated changes in the purchasing volume of its customers and the lack of claims made by customers, could have a significant impact on the sales incentives liability and reported operating results. The balance of accrued sales incentives at June 30, 2026 and December 31, 2025 was $13.8 million and $19.1 million, respectively, and is included within Accrued liabilities on the Unaudited Condensed Consolidated Balance Sheets.
(15)Leases
The Company has operating leases for certain sales, manufacturing, and engineering offices, as well as other vehicles and equipment, which are included within Patents and other assets, net on the Unaudited Condensed Consolidated Balance Sheets. The leases have remaining lease terms of less than 1 year to 6 years. The weighted average remaining lease term for operating leases as of June 30, 2026 was 2 years, with a weighted average discount rate of 4.6%.
Future minimum lease payments for operating leases as of June 30, 2026, were as follows:
| Year ending December 31, | |
|---|---|
| 2026 (excluding the six months ended June 30, 2026) | $1,767,725 |
| 2027 | 2,608,684 |
| 2028 | 1,996,606 |
| 2029 | 935,053 |
| 2030 | 376,170 |
| Thereafter | 140,395 |
| Total future minimum lease payments | 7,824,633 |
| Less imputed interest | (333,494) |
| Total | $7,491,139 |
| Accrued Liabilities | $3,047,121 |
|---|---|
| Other Non-Current Liabilities | 4,444,018 |
| Total | $7,491,139 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.